AC
GLUE icon

AXQ Capital’s Monte Rosa Therapeutics GLUE Stock Holding History

AXQ Capital’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$192K Sell
11,680
-2,062
-15% -$39.4K 0.02% 764
2025
Q4 		$215K Buy
+13,742
New +$185K 0.05% 547

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AXQ Capital's GLUE Position: Q1 2026 in Review

AXQ Capital reduced its Monte Rosa Therapeutics (GLUE) stake by 15% in Q1 2026, selling an estimated $39.4K and leaving 11,680 shares worth $192K. The position accounts for 0.02% of the portfolio, ranked #764.

AXQ Capital first reported a position in GLUE in Q4 2025 and has held it in 2 quarters since. The position peaked at $215K in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • AXQ Capital held 11,680 shares of Monte Rosa Therapeutics worth $192K as of Q1 2026.
  • AXQ Capital sold 2,062 Monte Rosa Therapeutics shares in Q1 2026, an estimated $39.4K.
  • Monte Rosa Therapeutics made up 0.02% of AXQ Capital's portfolio in Q1 2026, its #764 holding.
  • AXQ Capital first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • AXQ Capital's Monte Rosa Therapeutics position peaked at $215K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.